Can we withdraw anticoagulation in patients with antiphospholipid syndrome after seroconvertion?

S. Sciascia, E. Coloma-Bazán, M. Radin, M. L. Bertolaccini, C. López-Pedrera, Gerard Espinosa, P. L. Meroni, R. Cervera, M. J. Cuadrado

Research output: Contribution to journalReview article

7 Citations (Scopus)

Abstract

The current mainstay of treatment in patients with thrombotic antiphospholipid syndrome (APS) is long-term anticoagulation, mainly with Vitamin K antagonist agents. Some recently available studies have created new ground for discussion about the possible discontinuation of anticoagulation therapy in patients with a history of thrombotic APS in whom antiphospholipid antibodies (aPL) are not detected any longer (i.e. aPL seroconversion). We report the main points discussed at the last CORA Meeting regarding the issue whether or not anticoagulation can be stopped after aPL seroconversion. In particular, we systematically reviewed the available evidence investigating the clinical outcome of APS patients with aPL seroconversion in whom anticoagulation was stopped when compared to those in whom therapy was continued regardless the aPL profile. Furthermore, the molecular basis for the aPL pathogenicity, the available evidence of non-criteria aPL and their association with thrombosis are addressed. To date, available evidence is still limited to support the indication to stop oral anticoagulation therapy in patients with a previous diagnosis of thrombotic APS who subsequently developed a negative aPL profile. The identification of the whole risk profile for cardiovascular manifestations and possibly of a second level aPL testing in selected patients with aPL might support the eventual clinical decision but further investigation is warranted.

Original languageEnglish
Pages (from-to)1109-1114
Number of pages6
JournalAutoimmunity Reviews
Volume16
Issue number11
DOIs
Publication statusPublished - Nov 1 2017

Fingerprint

Antiphospholipid Antibodies
Antiphospholipid Syndrome
Clinical Decision Support Systems
Vitamin K
Therapeutics
Virulence
Thrombosis

Keywords

  • Anticoagulation
  • Antiphospholipid antibodies
  • Antiphosphospholipid syndrome
  • Thrombosis

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Cite this

Sciascia, S., Coloma-Bazán, E., Radin, M., Bertolaccini, M. L., López-Pedrera, C., Espinosa, G., ... Cuadrado, M. J. (2017). Can we withdraw anticoagulation in patients with antiphospholipid syndrome after seroconvertion? Autoimmunity Reviews, 16(11), 1109-1114. https://doi.org/10.1016/j.autrev.2017.09.004

Can we withdraw anticoagulation in patients with antiphospholipid syndrome after seroconvertion? / Sciascia, S.; Coloma-Bazán, E.; Radin, M.; Bertolaccini, M. L.; López-Pedrera, C.; Espinosa, Gerard; Meroni, P. L.; Cervera, R.; Cuadrado, M. J.

In: Autoimmunity Reviews, Vol. 16, No. 11, 01.11.2017, p. 1109-1114.

Research output: Contribution to journalReview article

Sciascia, S, Coloma-Bazán, E, Radin, M, Bertolaccini, ML, López-Pedrera, C, Espinosa, G, Meroni, PL, Cervera, R & Cuadrado, MJ 2017, 'Can we withdraw anticoagulation in patients with antiphospholipid syndrome after seroconvertion?', Autoimmunity Reviews, vol. 16, no. 11, pp. 1109-1114. https://doi.org/10.1016/j.autrev.2017.09.004
Sciascia S, Coloma-Bazán E, Radin M, Bertolaccini ML, López-Pedrera C, Espinosa G et al. Can we withdraw anticoagulation in patients with antiphospholipid syndrome after seroconvertion? Autoimmunity Reviews. 2017 Nov 1;16(11):1109-1114. https://doi.org/10.1016/j.autrev.2017.09.004
Sciascia, S. ; Coloma-Bazán, E. ; Radin, M. ; Bertolaccini, M. L. ; López-Pedrera, C. ; Espinosa, Gerard ; Meroni, P. L. ; Cervera, R. ; Cuadrado, M. J. / Can we withdraw anticoagulation in patients with antiphospholipid syndrome after seroconvertion?. In: Autoimmunity Reviews. 2017 ; Vol. 16, No. 11. pp. 1109-1114.
@article{125c6ea9ff574199a5d1267b247699bd,
title = "Can we withdraw anticoagulation in patients with antiphospholipid syndrome after seroconvertion?",
abstract = "The current mainstay of treatment in patients with thrombotic antiphospholipid syndrome (APS) is long-term anticoagulation, mainly with Vitamin K antagonist agents. Some recently available studies have created new ground for discussion about the possible discontinuation of anticoagulation therapy in patients with a history of thrombotic APS in whom antiphospholipid antibodies (aPL) are not detected any longer (i.e. aPL seroconversion). We report the main points discussed at the last CORA Meeting regarding the issue whether or not anticoagulation can be stopped after aPL seroconversion. In particular, we systematically reviewed the available evidence investigating the clinical outcome of APS patients with aPL seroconversion in whom anticoagulation was stopped when compared to those in whom therapy was continued regardless the aPL profile. Furthermore, the molecular basis for the aPL pathogenicity, the available evidence of non-criteria aPL and their association with thrombosis are addressed. To date, available evidence is still limited to support the indication to stop oral anticoagulation therapy in patients with a previous diagnosis of thrombotic APS who subsequently developed a negative aPL profile. The identification of the whole risk profile for cardiovascular manifestations and possibly of a second level aPL testing in selected patients with aPL might support the eventual clinical decision but further investigation is warranted.",
keywords = "Anticoagulation, Antiphospholipid antibodies, Antiphosphospholipid syndrome, Thrombosis",
author = "S. Sciascia and E. Coloma-Baz{\'a}n and M. Radin and Bertolaccini, {M. L.} and C. L{\'o}pez-Pedrera and Gerard Espinosa and Meroni, {P. L.} and R. Cervera and Cuadrado, {M. J.}",
year = "2017",
month = "11",
day = "1",
doi = "10.1016/j.autrev.2017.09.004",
language = "English",
volume = "16",
pages = "1109--1114",
journal = "Autoimmunity Reviews",
issn = "1568-9972",
publisher = "Elsevier",
number = "11",

}

TY - JOUR

T1 - Can we withdraw anticoagulation in patients with antiphospholipid syndrome after seroconvertion?

AU - Sciascia, S.

AU - Coloma-Bazán, E.

AU - Radin, M.

AU - Bertolaccini, M. L.

AU - López-Pedrera, C.

AU - Espinosa, Gerard

AU - Meroni, P. L.

AU - Cervera, R.

AU - Cuadrado, M. J.

PY - 2017/11/1

Y1 - 2017/11/1

N2 - The current mainstay of treatment in patients with thrombotic antiphospholipid syndrome (APS) is long-term anticoagulation, mainly with Vitamin K antagonist agents. Some recently available studies have created new ground for discussion about the possible discontinuation of anticoagulation therapy in patients with a history of thrombotic APS in whom antiphospholipid antibodies (aPL) are not detected any longer (i.e. aPL seroconversion). We report the main points discussed at the last CORA Meeting regarding the issue whether or not anticoagulation can be stopped after aPL seroconversion. In particular, we systematically reviewed the available evidence investigating the clinical outcome of APS patients with aPL seroconversion in whom anticoagulation was stopped when compared to those in whom therapy was continued regardless the aPL profile. Furthermore, the molecular basis for the aPL pathogenicity, the available evidence of non-criteria aPL and their association with thrombosis are addressed. To date, available evidence is still limited to support the indication to stop oral anticoagulation therapy in patients with a previous diagnosis of thrombotic APS who subsequently developed a negative aPL profile. The identification of the whole risk profile for cardiovascular manifestations and possibly of a second level aPL testing in selected patients with aPL might support the eventual clinical decision but further investigation is warranted.

AB - The current mainstay of treatment in patients with thrombotic antiphospholipid syndrome (APS) is long-term anticoagulation, mainly with Vitamin K antagonist agents. Some recently available studies have created new ground for discussion about the possible discontinuation of anticoagulation therapy in patients with a history of thrombotic APS in whom antiphospholipid antibodies (aPL) are not detected any longer (i.e. aPL seroconversion). We report the main points discussed at the last CORA Meeting regarding the issue whether or not anticoagulation can be stopped after aPL seroconversion. In particular, we systematically reviewed the available evidence investigating the clinical outcome of APS patients with aPL seroconversion in whom anticoagulation was stopped when compared to those in whom therapy was continued regardless the aPL profile. Furthermore, the molecular basis for the aPL pathogenicity, the available evidence of non-criteria aPL and their association with thrombosis are addressed. To date, available evidence is still limited to support the indication to stop oral anticoagulation therapy in patients with a previous diagnosis of thrombotic APS who subsequently developed a negative aPL profile. The identification of the whole risk profile for cardiovascular manifestations and possibly of a second level aPL testing in selected patients with aPL might support the eventual clinical decision but further investigation is warranted.

KW - Anticoagulation

KW - Antiphospholipid antibodies

KW - Antiphosphospholipid syndrome

KW - Thrombosis

UR - http://www.scopus.com/inward/record.url?scp=85030471356&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85030471356&partnerID=8YFLogxK

U2 - 10.1016/j.autrev.2017.09.004

DO - 10.1016/j.autrev.2017.09.004

M3 - Review article

AN - SCOPUS:85030471356

VL - 16

SP - 1109

EP - 1114

JO - Autoimmunity Reviews

JF - Autoimmunity Reviews

SN - 1568-9972

IS - 11

ER -